31
edits
Changes
Jump to navigation
Jump to search
Line 69:
Line 69: − + + Line 96:
Line 97: + + + + + + + + + + + +
Recurrent Genomic Alterations in Pediatric and Adult Central Nervous System Tumors Detected by Chromosomal Microarray (view source)
Revision as of 08:59, 16 November 2018
, 08:59, 16 November 2018no edit summary
'''Loss:''' CDKN2A/CDKN2B
'''Loss:''' CDKN2A/CDKN2B
| CDKN2A/CDKN2B loss may correlate with anaplastic histology
| CDKN2A/CDKN2B loss may correlate with anaplastic histology
| WHO CNS Tumors (2016), PMID:25318587; PMID:23096133; PMID:21274720
| WHO CNS Tumors (2016)<br>
PMID:25318587; PMID:23096133; PMID:21274720
|-
|-
|Glioblastoma, WHO grade IV
|Glioblastoma, WHO grade IV
|Overall poor prognosis regardless of subgroup
|Overall poor prognosis regardless of subgroup
|PMCID:3280796; PMID:24705254; PMID:24705252 PMID:27048880; PMID:26175967; PMID:24705251; PMID:28966033
|PMCID:3280796; PMID:24705254; PMID:24705252 PMID:27048880; PMID:26175967; PMID:24705251; PMID:28966033
|-
|'''EPENDYMOMA'''<br>
(in order of increasing WHO grade)
|
|'''DNA-based methylation classifies''' tumors across anatomical sites (posterior fossa, supratentorial, spinal), grades and age groups
|'''Fusion:''' YAP1 fusions (supratentorial tumors)<br>
'''Mutation:''' NF2 (spinal tumors)<br>
'''Loss:''' CDKN2A
|Intracranial (in children, 90%) or spinal tumors; Histological distinction between WHO grade II and III is of questionable relevance; Prognostic differences among tumors suggested on the basis of methylation analysis
|WHO CNS Tumors (2016)<br>
PMID:25965575; PMID:21627842; PMID:24939246; PMID:22516549
|-